Assay of tricyclic structured drugs and their metabolites in urine by high-performance liquid chromatography

Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs

Requirements for the provision of an efficient and reliable service for drugs of abuse screening in urine have been summarized in Part I of this review. The requirements included rapid turn-around times, good communications between requesting clinicians and the laboratory, and participation in quality assessment schemes. In addition, the need for checking/confirmation of positive results obtained for preliminary screening methods was stressed. This aspect of the service has assumed even greater importance with widespread use of dip-stick technology and the increasing number of reasons for which drug screening is performed. Many of these additional uses of drug screening have possible serious legal implications, for example, screening school pupils, professional footballers, parents involved in child custody cases, persons applying for renewal of a driving licence after disqualification for a drug-related offence, doctors seeking re-registration after removal for drug abuse, and checking for compliance with terms of probation orders; as well as pre-employment screening and work-place testing. In many cases these requests will be received from a general practitioner or drug clinic with no indication of the reason for which testing has been requested. This also raises the serious problems of a chain of custody, provision of two samples, stability of samples, and secure and lengthy storage of samples in the laboratory-samples may be requested by legal authorities several months after the initial testing. The need for confirmation of positive results is now widely accepted but it may be equally important to confirm unexpected negative results. Failure to detect the presence of maintenance drugs may lead to the patient being discharged from a drug treatment clinic and, if attendance at the clinic is one of the terms of continued employment, to dismissal. It seems likely that increasing abuse of drugs and the efforts of regulatory authorities to control this, will lead to the manufacture of more designer drugs. Production of substituted phenethylamines was facilitated by the drug makers' cook book, 'PIHKAL' (Phenethylamines I Have Known And Loved) by Dr Alexander Shulgin and Ann Shulgin, and production of substituted tryptamines is promised in their next book, TIHKAL. Looking to the future, laboratories will need to ensure that they can detect and quantitate an ever-increasing number of drugs and related substances. The question of confidence in results of drugs of abuse testing raised in 1993 by Watson has assumed even greater importance as a result of attention focused on the OJ Simpson trial in Los Angeles. Toxicological investigations are likely to be challenged more frequently in the future. Even if analyses have been performed by GC-MS, there is a need to establish the level of match between the spectrum of the unknown substance and a library spectrum which is considered acceptable for legal purposes. It will also be essential to ensure that computer libraries contain spectra for all substances likely to be encountered in drugs of abuse screening.

Determination of metapramine, imipramine, trimipramine and their major metabolites in plasma by reversed-phase column liquid chromatography

The determination of metapramine, imipramine, trimipramine and their desmethyl metabolites after alkaline diethyl ether extraction from plasma is achieved by column liquid chromatography using two internal standards and mu Bondapak C18 column. Elution is carried out isocratically at 1 or 0.6 ml min-1 with two mixtures of acetonitrile-potassium dihydrogen phosphate-distilled water (45:55:10 for metapramine and its metabolites; 45:50:5 for imipramine, trimipramine and their metabolites). Detection is monitored by absorption at 254 nm. The detection limit is less than 5 ng ml-1 for each compound. The coefficients of variation (within-day and day-to-day) for the eight compounds are less than 11.3%. Interference from several possible co-medications is discussed. The technique can be used for routine therapeutic monitoring of the antidepressants as well as analytical toxicology. However, the three antidepressants cannot be analysed simultaneously by this method because metapramine requires a different elution system and imipramine interferes with monodesmethyltrimipramine (retention times 8.90 and 8.60 min, respectively).

Determination of piquindone in canine plasma and urine by high-performance liquid chromatography

This report describes a rapid, sensitive and selective method for the determination of piquindone in canine plasma and piquindone and the N-demethyl metabolite of piquindone in canine urine, utilizing normal-phase high-performance liquid chromatography (HPLC) with isocratic elution at ambient temperature and monitoring the ultraviolet absorbance of the eluent at 254 nm. The trimethyl analogue of piquindone is used as the internal standard in the HPLC assay of plasma. The assay was applied to the measurement of concentrations of piquindone in the plasma and urine of a dog following single intravenous and oral administration of 5 mg/kg doses of piquindone hydrochloride dihydrate.

The analysis of tricyclic antidepressant drugs at therapeutic blood levels by reversed-phase high-performance liquid chromatography using pairing and organic counter-ions

A serum assay method incorporating two internal standards suitable for routine clinical analysis of tricyclic antidepressant drugs at the therapeutic level is described. The method involves extraction and chromatography using a reversed-phase high-performance liquid chromatography system incorporating pairing and organic counter-ions. The quantitative characteristics of the method are reported and results are compared with consensus values for four commonly encountered drugs, amitriptyline, nortriptyline, imipramine and desipramine. The method is shown to be applicable to more recently developed antidepressants such as nomifensine and maprotiline and the flexibility of the chromatography is discussed. Sample chromatograms obtained from patient samples in the presence and absence of potentially interfering drugs and metabolites are discussed.

A TLC fluorescence derivatization assay for chlorpromazine and its non-conjugated hepatic microsomal metabolites

Procedures for the assay of chlorpromazine (CPZ) and its metabolites were compared. An improved assay, involving organic extraction, thin-layer chromatography and fluorescence derivatization, was developed. The compounds were extracted from microsomal protein suspensions into 15% n-propanol in dichloromethane by successive extractions at pH 2 and pH 12. CPZ and its mono- and di-desmethyl, 7-hydroxy, N-oxide, sulphoxide and N-oxide-sulphoxide metabolites were separated using TLC on silica gel developed with methanol-acetone-ammonia (50:50:1 v/v/v). The compounds were extracted from the TLC plate with chloroform-methanol (2:1 v/v) and subjected to oxidation with hydrogen peroxide. The highly fluorescent oxidized derivatives were identified as sulphoxides by their fluorescence characteristics. Amounts of derivatized CPZ and metabolites were measured using derivatized promazine as the internal standard.

Simultaneous analysis of imipramine and its metabolite desipramine in biological fluids

A method for the simultaneous quantitation of imipramine and its N-demethylated metabolite desipramine at the nanogram level in a single gas chromatograph peak is presented, utilizing gas chromatography-mass spectrometry with selected ion recording. The assay is specific and quantitation is achieved using [2H4]imipramine as the internal standard. The method involves the in situ methylation of desipramine with [2H2]formaldehyde and sodium borohydride to give [2H2]imipramine. Quantitation is then achieved by selected ion recording at m/z 280, 282 and 284, whence the ratio of the ion currents at 280/284 and at 282/284 gives the quantities of imipramine and desipramine respectively.

Determination of clomipramine or imipramine and their mono-demethylated metabolites in human blood or plasma by high-performance liquid chromatography

A high-performance liquid chromatographic method for the quantitative assay of clomipramine or imipramine and their mono-demethylated metabolites in human blood or plasma is described. After addition of the internal standards, imipramine for clomipramine, desipramine for desmethylclomipramine and conversely, the compounds are extracted from blood or plasma at pH 10 into heptane containing 1% isoamyl alcohol; they are then back-extracted into an acidic aqueous phase and re-extracted at a basic pH into heptane. After evaporation, the residue is dissolved in 300 microliters of mobile phase and 150 microliters is injected. Both drugs and their mono-demethylated metabolites are well separated from the blood or plasma components and the other metabolites on a silica gel column using ethanol--hexane-dichloromethane-diethylamine (30:62:8:5 . 10(-3)) as the mobile phase at a flow-rate of 1.5 ml/min. The limit of sensitivity is 5 ng/ml for clomipramine and imipramine and 10 ng/ml for the corresponding mono-demethylated metabolites. This method has been used to analyse plasma from subjects given therapeutic doses of clomipramine or imipramine.

Ion-pair liquid chromatography of amitriptyline and metabolites in plasma

A method is described for the determination of amitriptyline and nortriptyline in the plasma of patients during treatment. The method is based on liquid chromatography of the amines as ion-pairs with perchlorate. The separation column is packed with silica gel, and a mixture of diisopropyl ether, dichloromethane, methanol and water containing the counter ion is used as eluent. High efficacy and stability of the system is achieved. The separation of metabolites is demonstrated. The cis- and trans-10-hydroxy isomers of amitriptyline and nortriptyline are easily resolved with this chromatographic system.